B. Braun OEM Division - System-built Solutions. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

B. Braun OEM Division – System-built Solutions.

Expertise in contract manufacturing and infusion therapy products

B. Braun supplies healthcare markets worldwide and is employing approx. 48,000 individuals. Based on this expertise the B. Braun OEM Division serves the pharmaceutical and medical devices industry.

At B. Braun OEM we offer contract manufacturing for infusion, irrigation and volume replacement solutions as well as standard injectables, anesthetics and dermatological products like creams, gels and pomades. Depending on the product requirements, we can fill in containers of different sizes, shapes and materials.

Furthermore, we provide a wide range of infusion therapy products. We supply all that is needed to admixture and infuse or inject a drug. You can order standard products or a customized version.

Partnering with us provides you with complete outsourcing knowledge. Our project management teams are the experts for individual customer ideas.

We can handle manufacturing projects and will customize a product or set according to your detailed specifications.

Products:

  • Pharmaceutical Solutions
  • Medical Devices
  • Products for Disinfection and Hygiene

Project management services:

  • Customized Products (modified characteristics, private label etc.)
  • Customized Sets Pharmaceutical
  • Contract Manufacturing
  • Common Development

B. Braun Melsungen AG
Website: www.bbraunoem.com
E-mail: info-europe@bbraunoem.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
FindPharma Custom Search

Click here